Unicycive Therapeutics (UNCY) Operating Income (2020 - 2026)
Unicycive Therapeutics posted quarterly Operating Income of -$8.4 million for Q1 2026, down 5.61% year-on-year from -$8.9 million in Q1 2025, and down 16.79% on a QoQ basis from -$7.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Operating Income data on file, last reported at -$8.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 5.61% year-over-year to -$8.4 million; the trailing twelve-month figure through Mar 2026 stood at -$30.0 million (up 3.03% YoY), and the FY2025 full-year result was -$29.5 million, up 8.1% from the prior year.
- Operating Income for Q1 2026 stood at -$8.4 million, down from -$7.2 million in the prior quarter.
- Across five years, Operating Income topped out at -$3.5 million in Q1 2022 and bottomed at -$9.3 million in Q4 2024.
- The 5-year median for Operating Income is -$6.3 million (2023), against an average of -$6.4 million.
- The widest annual swing landed in 2022, when Operating Income sank 383.86%; it then grew 22.0% in 2025.
- A 5-year view of Operating Income shows it stood at -$5.3 million in 2022, then fell by 18.55% to -$6.3 million in 2023, then plunged by 46.7% to -$9.3 million in 2024, then climbed by 22.0% to -$7.2 million in 2025, then slipped by 16.79% to -$8.4 million in 2026.
- The last three Operating Income figures came in at -$8.4 million (Q1 2026), -$7.2 million (Q4 2025), and -$7.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -8.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.44 Mn |
| Dec 31, 2025 | -7.22 Mn |
| Sep 30, 2025 | -7.34 Mn |
| Jun 30, 2025 | -6.96 Mn |
| Mar 31, 2025 | -7.99 Mn |
| Dec 31, 2024 | -9.26 Mn |
| Sep 30, 2024 | -6.25 Mn |
| Jun 30, 2024 | -7.40 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Dec 31, 2023 | -6.31 Mn |
| Sep 30, 2023 | -5.94 Mn |
| Jun 30, 2023 | -4.32 Mn |
| Mar 31, 2023 | -4.20 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.55 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -4.72 Mn |
| Jun 30, 2021 | -779,000.00 |
| Mar 31, 2021 | -731,000.00 |
| Dec 31, 2020 | -717,000.00 |
| Sep 30, 2020 | -626,000.00 |
| Jun 30, 2020 | -336,000.00 |